Navigation Links
Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
Date:12/17/2008

EMERYVILLE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that an independent Data Safety Monitoring Board (DSMB) has determined that the current clinical trials of Viprinex(TM) for the treatment of acute ischemic stroke are unlikely to show benefit. As a result, the company has terminated further enrollment in the trials. NTI will obtain and analyze the data before evaluating the potential for any future development of Viprinex. The interim analysis conducted by the DSMB evaluated stroke patients' outcome 90 days following an acute ischemic stroke, comparing treatment with Viprinex to treatment with placebo. The DSMB determined that there was no clinically meaningful difference in outcome between the two treatment groups as measured on the modified Rankin scale of disability, the primary endpoint of the study.

"We are deeply disappointed that Viprinex did not improve overall patient outcomes in our clinical study," said Paul E. Freiman, president and chief executive officer. "This news is a significant set-back for our clinical program. Once we obtain the data and we have analyzed the results from this study, which we expect to occur in early 2009, we will determine whether we will pursue any further development of Viprinex. In the meantime, we are implementing plans we have developed to reduce our expenses, which will likely result in a significant reduction in our overall headcount if we determine that future development of Viprinex is not warranted."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
2. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
5. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
6. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
7. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
8. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
9. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... N.Y. , Dec. 15, 2014 As ... SPL (Structured Product Labeling) markup language standard, content teams ... understanding and skills to work with the standard. Starting ... series of three webinars on the benefits and the ... one-hour webinars will be facilitated by Howard Shatz ...
(Date:12/14/2014)... GREENVILLE, S.C. , Dec. 14, 2014  ChartSpan, ... become the most downloaded iPhone and iPad medical app ... Photo - http://photos.prnewswire.com/prnh/20141214/164317 ... with the ability to request, manage and send electronic ... of innovative entrepreneurs who grew tired of waiting for ...
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... Sept. 22 AstraZeneca today,announced that the United ... additional six-month period of exclusivity to market CASODEX(R),(bicalutamide) ... 1, 2009. AstraZeneca has been working with the ... of CASODEX in a pediatric,setting but will not ...
... a biotech company,focused on developing novel therapeutics for ... commercial and manufacturing expertise to,the Company,s senior management ... clinical trials of ENB-0040 for the treatment of,hypophosphatasia., ... Enobia,s Vice President, Chief,Commercial Officer, and Jayant Aphale, ...
Cached Medicine Technology:AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 2AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 3AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 4Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 2Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 3
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... Cancer researchers have just published an important new report ... pleural mesothelioma. Surviving Mesothelioma has just posted an article ... to read it now. , Doctors at Harvard, ... York’s Langone Medical Center performed complete genetic analyses on ... effort to pinpoint the genes that are most likely ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), ... a new study providing evidence on the impact of ... children. , Sufficient enough evidence already exists showing a ... juice drinks, with the onset of tooth decay. One ... listed as 100% fruit juice, meaning it is completely ...
(Date:12/15/2014)... a leading mobile app development company , custom ... which allows users to keep track of wines they ... right wine. At the center of WineMatch is ... wine information. All this information is assembled to help ... are close counterparts to one another are called Matches. ...
(Date:12/15/2014)... 15, 2014 Health Dialog, a ... today that it has received Patient Oriented Accreditation ... for its Disease Management (DM) Programs for asthma, ... coronary heart disease and diabetes. This marks the ... Health Dialog’s Disease Management (DM) Programs, reaffirming Health ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... traditional Indian medicine, a four-year degree course in Ayurveda ... for the first time in eastern India//. ... its kind in the country after Gujarat, would be ... in joint venture with West Bengal Health Department under ...
... postmenopausal women has shown that those who indulged in six ... a 3 percent reduction in risk of type 2 diabetes, ... the scientists were not able to place their finger on ... yet they strongly feel that the presence of antioxidants and ...
... Now, Britain's reputed pediatricians, nearly 30 of them have called ... ,Infact they have issued a letter to the public ,that ... triple shots of MMR. ,They have appealed to the ... furore over the supposed link between MMR and autism, especially ...
... a University of Alabama biostatistician has compiled a report on ... assisted in this venture by 19 other scientists in the ... at more than 100 studies on the reasons for obesity ... could be an answer ,* Inadequate sleep: Sleep ...
... in New Zealand. Hence Pharmac decided to fund for the new ... level. // ,It has decided to give Insulin Glargine ... , Murray Dear who is the president for the Diabetes New ... the incidence of diabetes. ,He also said that the ...
... could increase their chances of breast cancer, a study says. ... Agency for Research on Cancer in France analysed 1,600 women. ... susceptibility genes) mutations who had undergone a chest X-ray were ... who had never undergone the procedure. ,Women who ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: